View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, May 25 (HealthDay News) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published online May 21 in the British Journal of Dermatology.
Marieke H. Roozeboom, M.D., from the Maastricht University Medical Centre in the Netherlands, and colleagues conducted a systematic literature review to determine residue, recurrence, and tumor-free survival for patients with sBCC treated with frequently used therapies. Thirty-six (14 randomized and 22 nonrandomized) studies were included.
The researchers found that, based on 28 studies, the pooled estimates of percentages of sBCC with complete response 12 weeks after treatment were 86.2 percent for imiquimod and 79.0 percent for PDT. At one year, tumor-free survival was 87.3 percent for imiquimod and 84 percent for PDT, based on pooled estimates from 23 studies. Treatment results with 5-fluorouracil, surgical excision, and cryotherapy were reported by a small number of studies.
"Pooled estimates from randomized and nonrandomized studies showed similar tumor-free survival at one year for imiquimod and PDT," the authors write. "There is a need for head-to-head comparison studies between PDT, imiquimod, and other treatments with long-term follow-up to enable better recommendations for optimal sBCC treatment."
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top